A novel mathematical model of AIDS-associated Kaposi's sarcoma: Analysis and optimal control

被引:4
|
作者
Kaondera-Shava, R. F. [1 ]
Lungu, E. [1 ]
Szomolay, B. [2 ]
机构
[1] Botswana Int Univ Sci & Technol, Dept Math & Stat Sci, Private Bag 16, Palapye, Botswana
[2] Cardiff Univ, Sch Med, Syst Immun Res Inst, Cardiff CF14 4XN, Wales
关键词
Kaposi's sarcoma; cART; Optimal control; Viral load; HIV-1; KSHV; INFECTION; DYNAMICS; CHEMOTHERAPY; SENSITIVITY; UNCERTAINTY; GROWTH;
D O I
10.1016/j.biosystems.2020.104318
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Kaposi's sarcoma (KS) has been the most common HHV-8 virus-induced neoplasm associated with HIV-1 infection. Although the standard KS therapy has not changed in 20 years, not all cases of KS will respond to the same therapy. The goal of current AIDS-KS treatment modalities is to reconstitute the immune system and suppress HIV-1 replication, but newer treatment modalities are on horizon. There are very few mathematical models that have included HIV-1 viral load (VL) measures, despite VL being a key determinant of treatment outcome. Here we introduce a mathematical model that consolidates the effect of both HIV-1 and HHV-8 VL on KS tumor progression by incorporating low or high VLs into the proliferation terms of the immune cell populations. Regulation of HIV-1/HHV-8 VL and viral reservoir cells is crucial for restoring a patient to an asymptomatic stage. Therefore, an optimal control strategy given by a combined antiretroviral therapy (cART) is derived. The results indicate that the drug treatment strategies are capable of removing the viral reservoirs faster and consequently, the HIV-1 and KS tumor burden is reduced. The predictions of the mathematical model have the potential to offer more effective therapeutic interventions based on viral and virus-infected cell load and support new studies addressing the superiority of VL over CD4(+) T-cell count in HIV-1 pathogenesis.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] AIDS-associated Kaposi's sarcoma
    Kroll, MH
    Shandera, WX
    HOSPITAL PRACTICE, 1998, 33 (04): : 85 - +
  • [2] Extensive AIDS-associated Kaposi's sarcoma
    Medina-Pinon, Isai
    Wah-Suarez, Martin
    Arturo Acosta-Calderon, Luis
    Ramos-Jimenez, Javier
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 67 : 137 - 138
  • [3] Paclitaxel for AIDS-associated Kaposi's sarcoma
    Dhillon, T
    Stebbing, J
    Bower, M
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (02) : 215 - 219
  • [4] Foscarnet and AIDS-associated Kaposi's sarcoma
    Cordero, E
    LopezCortes, LF
    Viciana, P
    Alarcon, A
    Pachon, J
    AIDS, 1997, 11 (14) : 1787 - 1788
  • [5] AIDS-Associated Kaposi Sarcoma
    Clark, Kevin R.
    RADIOLOGIC TECHNOLOGY, 2023, 94 (06) : 464 - 467
  • [6] Geography of AIDS-associated Kaposi's sarcoma in Europe
    Ebrahim, SH
    Peterman, TA
    Zaidi, AA
    Hamers, FF
    AIDS, 1997, 11 (14) : 1739 - 1745
  • [7] AIDS-associated Kaposi's sarcoma of the conjunctiva in a woman
    Bavishi, A.
    Ashraf, A.
    Lee, L.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2012, 23 (03) : 221 - 222
  • [8] AIDS-ASSOCIATED KAPOSI'S SARCOMA IN SOKOTO, NIGERIA
    Mbah, N.
    Abdulkareem, I. H.
    Panti, A.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2008, 11 (03) : 181 - 184
  • [9] Disseminated AIDS-associated Kaposi's sarcoma in pregnancy
    Sebitloane, H. M.
    Mosam, A.
    Moodley, J.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2006, 96 (07): : 602 - 603
  • [10] AIDS-ASSOCIATED KAPOSI-SARCOMA
    CHAUDHRY, AP
    CHACHOUA, A
    SALTZMAN, BR
    FRIEDMANKIEN, AE
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1987, 115 (06): : 824 - &